We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

112 hedge funds and large institutions have $133M invested in Provention Bio, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more call options, than puts

Call options by funds: $4.5M | Put options by funds: $1.63M

8% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 37

9% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 22

3% less funds holding

Funds holding: 115 → 112 (-3)

7% less capital invested

Capital invested by funds: $143M → $133M (-$10M)

Holders
112
Holders Change
-3
Holders Change %
-2.61%
% of All Funds
1.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
34
Reduced
37
Closed
22
Calls
$4.5M
Puts
$1.63M
Net Calls
+$2.87M
Net Calls Change
+$1.58M

Top Buyers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
+$10.8M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$4.93M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$646K
4
DCM
DG Capital Management
New York
+$479K
5
Bank of America
Bank of America
North Carolina
+$398K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.51M
2
State Street
State Street
Massachusetts
-$1.35M
3
6CM
683 Capital Management
New York
-$1.27M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.03M
5
SG Americas Securities
SG Americas Securities
New York
-$945K
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
1
Sessa Capital
New York
$33.1M +$10.8M +1,700,409 +41%
BlackRock
2
BlackRock
New York
$25.2M -$43.2K -6,801 -0.2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$14M -$1.03M -162,914 -6%
Verition Fund Management
4
Verition Fund Management
Connecticut
$8.39M +$4.93M +776,835 +109%
State Street
5
State Street
Massachusetts
$6.82M -$1.35M -213,028 -15%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$5.37M -$538K -84,772 -8%
PA
7
Perceptive Advisors
New York
$5.33M – – –
DCM
8
DG Capital Management
New York
$3.48M +$479K +75,485 +14%
Millennium Management
9
Millennium Management
New York
$3.07M -$1.51M -237,320 -30%
Northern Trust
10
Northern Trust
Illinois
$3.03M -$168K -26,382 -5%
N
11
Nuveen
North Carolina
$2.51M +$52.9K +8,335 +2%
Goldman Sachs
12
Goldman Sachs
New York
$1.51M +$383K +60,343 +29%
AR
13
Advisory Research
Illinois
$1.32M -$15.9K -2,500 -1%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$1.21M -$81.3K -12,806 -6%
RHJA
15
Rice Hall James & Associates
California
$1.16M -$223K -35,196 -15%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$1.08M +$646K +101,739 +112%
Morgan Stanley
17
Morgan Stanley
New York
$996K -$228K -35,858 -17%
Citadel Advisors
18
Citadel Advisors
Florida
$918K +$140K +22,121 +16%
PPA
19
Parametric Portfolio Associates
Washington
$901K -$127K -19,976 -11%
Truist Financial
20
Truist Financial
North Carolina
$843K -$31.8K -5,000 -3%
Charles Schwab
21
Charles Schwab
California
$807K +$32.8K +5,168 +4%
SPC
22
Sigma Planning Corp
Michigan
$686K +$10.5K +1,650 +1%
Swiss National Bank
23
Swiss National Bank
Switzerland
$589K – – –
Bank of America
24
Bank of America
North Carolina
$578K +$398K +62,725 +156%
AllianceBernstein
25
AllianceBernstein
Tennessee
$487K – – –
1
2 3 4 5

PRVB Hedge Fund Activity: Q4 2021 in Review

112 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2021, worth a combined $133M — down 7% from $143M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of PRVB and 20 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 34 added.

The largest buyer was Sessa Capital, adding an estimated $10.8M. The largest seller was Millennium Management, cutting an estimated $1.51M.

  • 112 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2021, down from 115 in Q3 2021.
  • Funds reported $133M of Provention Bio, Inc. Common Stock stock for Q4 2021, down 7% quarter-over-quarter.
  • 20 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2021 and 22 closed out, a net change of -2 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q4 2021 was Sessa Capital, an estimated $10.8M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $1.51M sold.

Based on aggregated 13F filings for Q4 2021.